Synergism of calycosin and bone marrow-derived mesenchymal stem cells to combat podocyte apoptosis to alleviate adriamycin-induced focal segmental glomerulosclerosis

Figure 5 Calycosin pretreatment enhances the ability of mesenchymal stem cells to inhibit apoptosis in adriamycin-stimulated mouse podocyte cells. A and B: Expression of Bax and Bcl-2 in each group as determined by immunofluorescence staining. Bar = 50 μm; C-E: Protein expression levels of Bax and Bcl-2 detected by Western blot and normalized to control. Data are expressed as the mean ± SD (n = 3). ^bP < 0.001. NC: Normal control; ADR: Adriamycin; MSCs: Mesenchymal stem cells; CA: Calycosin; MSCs^CA: Mesenchymal stem cells pretreated with calycosin.